Trial Profile
A PHASE 2 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, 20-WEEK SAFETY, TOLERABILITY, AND EFFICACY STUDY OF PD 0360324 IN ADULT SUBJECTS WITH CHRONIC PULMONARY SARCOIDOSIS
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Jan 2020
Price :
$35
*
At a glance
- Drugs PD 360324 (Primary)
- Indications Pulmonary sarcoidosis
- Focus Therapeutic Use
- Sponsors Pfizer
- 12 Aug 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
- 13 Jan 2014 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.
- 16 Dec 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.